Molecular Formula | C17H18N2O4 |
Molar Mass | 314.34 |
Solubility | 10 mM in DMSO |
Appearance | powder |
Color | white to beige |
Storage Condition | 2-8°C |
In vitro study | In normal (HFS) and transformed (LNCaP, A549, and U87) cells, HPOB induces acetylation of α-tubulin, however, not histones, and inhibits cell growth, however, not viability. In HFS cells, HPOB enhances transformed cell death induced by etoposide, doxorubicin, or SAHA. HPOB also enhancing etoposide-induced transformed cell death via the apoptotic pathway in transformed cells. |
In vivo study | In mice bearing CWR22 human prostate cancer xenografts, HPOB (300 mg/kg/d i.p.), when in combination with SAHA, causes suppression of the growth of established tumors, while produces no significant suppression when used alone. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.181 ml | 15.907 ml | 31.813 ml |
5 mM | 0.636 ml | 3.181 ml | 6.363 ml |
10 mM | 0.318 ml | 1.591 ml | 3.181 ml |
5 mM | 0.064 ml | 0.318 ml | 0.636 ml |
biological activity | HPOB is an effective, selective HDAC6 inhibitor with IC50 of 56 nM, which is more than 30 times higher than other HDACs. |
in vitro study | in normal (HFS) and transformed (LNCaP, A549, and U87) cells, HPOB induces acetylation of α-tubulin, however, not histones, and inhibits cell growth, however, not viability. In HFS cells, HPOB enhances transformed cell death induced by etoposide, doxorubicin, or SAHA. HPOB also enhancing etoposide-induced transformed cell death via the apoptotic pathway in transformed cells. |
in vivo research | in mice bearing CWR22 human prostate cancer xenografts, HPOB (300 mg/kg/d I. p.), when in combination with SAHA, uses suppression of the growth of established tumors, while produces no significant suppression when used alone. |